enGene Holdings Inc. (ENGN) Research

Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.

Market snapshot

Symbol
ENGN
Price
$1.72
Day change
-1.15%
Market cap
$88.1M
P/E ratio
-1.81x
52-week range
1.4-12.25
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 3 months
Analyst price target
$6.13

Peer companies

  • AC Immune S.A. (ACIU)
  • Altimmune, Inc. (ALT)
  • Amarin Corporation plc (AMRN)
  • Annexon, Inc. (ANNX)
  • Alto Neuroscience, Inc. (ANRO)
  • Cellectis S.A. (CLLS)
  • DBV Technologies S.A. (DBVT)
  • Korro Bio, Inc. (KRRO)

Recent insider activity

  • Astley-Sparke Philip — A-Award (31000 shares) on 2026-06-16
  • BRUNK GERALD A — A-Award (31000 shares) on 2026-06-16
  • Glickman Richard M — A-Award (31000 shares) on 2026-06-16
  • Grossman William — A-Award (200000 shares) on 2026-06-16
  • Grossman William — A-Award (31000 shares) on 2026-06-16

Open enGene Holdings Inc. (ENGN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.